ProMIS Neurosciences to Develop TDP-43-Targeting Therapies

Toronto-based biotech company ProMIS Neurosciences (formerly Amorfix Life Sciences) announced initiation of a program to identify and develop therapeutic antibodies that target disease-associated variants of TDP-43. TDP-43 is an RNA-binding protein that normally localized to the nucleus, but in ALS and FTD, it accumulates in pathological cytosolic aggregates that interfere with normal cellular functions (see Feb 2014 news). The company plans to use its specialized computational platforms to predict novel epitopes on toxic variants of TDP-43, and design antibodies to selectively target these forms, while  retaining crucial functions of the native protein (see March 2014 news).

Click here to read the press release.

amorfix disease-als disease-ftd promis tdp-43 topic-preclinical topic-randd
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail